Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Businessweek Archives

A Strong Pulse At Medtronic

Inside Wall Street


Big is beautiful, says Richard Hughes. That is, large-cap, growth-oriented companies such as Coca-Cola and General Electric are the only stocks Hughes loves--or owns. But since there aren't many such giants around, Hughes, president of Rittenhouse Financial Services, scours the world for the future Cokes and GEs. This big-stock strategy has powered Rittenhouse, acquired by Nuveen in September, to a 19.6% yearly cumulative gain since 1983. Last year, Rittenhouse's 38% gain beat the S&P 500's 33%.

So what's the next up-and-comer on Hughes's screen? Medtronic (MDT), the world's leading maker of heart pacemakers and defibrillators. Hughes, who has been accumulating Medtronic for Rittenhouse's $5 billion portfolio, admits it's not yet a household name. "But if you simply look at its consistent earnings growth and other fundamentals, you might think it was Coke or GE," says Hughes.

Earnings have been growing at least 17% a year, he notes. Now trading at 55 7/8 a share, with a price-earnings ratio of 35, Medtronic is cheap, based on its growth rate and long-term value, says Hughes. "Demographic trends favor the market that Medtronic dominates," he argues. With the baby boomers aging and more people living longer, demand for Medtronic's devices will rise. "Medtronic is at the forefront of prolonging people's lives," says Hughes.

Some two-thirds of sales come from its pacing products, chiefly bradycardia devices, which adjust slow or irregular heartbeats, and tachyarrhythmia devices, which correct rapid heartbeats. Other products include mechanical and tissue heart valves.

Analysts expect Medtronic to earn $1.30 a share this year and $1.56 in 1999, up from $1.11 in 1997.BY GENE G. MARCIALReturn to top

Return to top

blog comments powered by Disqus